Sight Sciences, Inc. (SGHT) News
Follow Sight Sciences, Inc. (SGHT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Sight Sciences Q3 Revenue Reaches $24.9 Million, Above Estimate
Q3 revenue was $24.9 million versus an IBES estimate of $23.5 million. The company reported operating expenses of $27.5 million.
EQUITY | Nov 04, 2026, 09:13 PM UTC
L
SGHT: Strong growth in glaucoma and dry eye platforms, with new products and expanded market access ahead
The business has shifted to a high-growth, dual-platform model with strong momentum in both glaucoma and dry eye interventions. Recent payer wins, product innovation, and operational discipline are driving revenue growth
NEWS | Sep 15, 2026, 02:36 PM UTC
L
SGHT: Double-digit growth, new product launches, and expanding payer access drive strong momentum
Strong double-digit revenue growth was driven by both glaucoma and dry eye businesses, with OMNI and TearCare expanding rapidly following payer wins and product innovation. The company is launching OMNI Ultra, expanding
NEWS | Sep 15, 2026, 02:04 PM UTC
L
Sight Sciences to present at Morgan Stanley Global Healthcare conference Sept. 15
Sight Sciences says it will present at the upcoming Morgan Stanley Global Healthcare Conference on Sept. 15.
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
Sight Sciences to present at Morgan Stanley Global Healthcare conference
Sight Sciences plans to present at the Morgan Stanley Global Healthcare Conference on September 15.
EQUITY | Sep 01, 2026, 08:05 PM UTC
M
SGHT TearCare gains first-only MGD indication for evaporative dry eye
SGHT says its TearCare is the first and only treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease.
REGULATION | Aug 19, 2026, 11:05 AM UTC
L
Sight Sciences Raises FY2026 Sales Guidance from $83.000M-$89.000M to $88.000M-$92.000M vs $86.083M Est
Sight Sciences (NASDAQ: SGHT ) raises FY2026 sales outlook from $83.000 million-$89.000 million to $88.000 million-$92.000 million vs $86.083 million estimate.
EARNINGS | Aug 05, 2026, 08:35 PM UTC
H
Sight Sciences Announces Aetna Coverage
Aetna covers Sight Sciences' surgical systems
EQUITY | Aug 05, 2026, 08:04 PM UTC
H
Why Arista Networks Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of Arista Networks Inc (NYSE: ANET ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued strong third-quarter guidance. Arista Networks re
EARNINGS | Aug 05, 2026, 08:57 AM UTC
L
SGHT - Sight Sciences Receives FDA 510 (k) Clearance of the OMNI Ultra Surgical System
SGHT - Sight Sciences Receives FDA 510 (k) Clearance of the OMNI Ultra Surgical System
REGULATION | Aug 04, 2026, 09:37 PM UTC
L
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutr
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutral rated RXST, Buy rated SGHT) and initiating coverage of Buy rated BLCO, Neutra
EQUITY | Jul 28, 2026, 11:52 AM UTC
L
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
EQUITY | Jul 28, 2026, 11:47 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
H
Sight Sciences price target raised to $6 from $5.15 at Citi
Citi raised the firm's price target on Sight Sciences to $6 from $5.15 and keeps a Neutral rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medtech s
EARNINGS | Jul 08, 2026, 10:37 AM UTC